home / stock / hcm / hcm news

HCM News and Press, HUTCHMED (China) Limited From 11/01/23

Stock Information
Company Name: HUTCHMED (China) Limited
Stock Symbol: HCM
Market: NASDAQ
Website: hutch-med.com
Menu
HCM HCM Quote HCM Short HCM News HCM Articles HCM Message Board
Get HCM Alerts

News, Short Squeeze, Breakout and More Instantly...
HCM - International companies to host live webcasts at Deutsche Bank's Depositary Receipts

NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference (“dbVIC”) on Wednesday, November 8 and Thursday, November 9, featuring live webcast presentations from international companies with American D...
HCM - Hutchmed: Progressing, But We Would Like More Clarity On Profit Margins

2023-10-19 18:23:58 ET Summary Hutchmed's 2023 interim financial report shows progress towards profitability, with revenue from product sales and R&D services increasing. The company has a strong balance sheet with $856 million in cash and a low level of bank borrowings. T...

HCM - HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2023

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Oct. 16, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that new and updated clinical data from several ongoing studies of fruquintinib, in combinati...

HCM - Phio Pharmaceuticals, Exscientia among healthcare movers

2023-10-11 10:00:00 ET More on Health Care Select Sector SPDR BofA reports 10th consecutive week of equity inflows Citi turns cautious on pharmaceuticals and biotech Seeking Alpha’s Quant Rating on Health Care Select Sector SPDR For further details see...
HCM - HUTCHMED Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Sept. 29, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (Nasdaq/AIM:​HCM, HKEX:​13) (“ HUTCHMED ”) today announced that Takeda ( TSE:4502/​NYSE:TAK ) has submitted a New Drug Application (“...

HCM - HUTCHMED Highlights Presentation of Results from the Phase IIIb Trial of Savolitinib at the 2023 World Conference of Lung Cancer

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 12, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM: HCM, HKEX: 13) today announces that results from the confirmatory Phase IIIb clinical trial of savolitinib in patients with mesenchymal epitheli...

HCM - HUTCHMED Completes Patient Enrollment of a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 11, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that it has completed patient enrollment of a bridging study of tazemetostat in China. The br...
HCM - HUTCHMED Receives Breakthrough Therapy Designation in China for Savolitinib for Gastric Cancer

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Aug. 28, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that the Center for Drug Evaluation of China’s National Medical Products Administratio...

HCM - Hutchmed says Chinese Phase 3 sovleplenib study meets primary endpoint

2023-08-21 11:31:53 ET More on Hutchison China MediTech Hutchmed: Attractive Chinese R&D Giant HUTCHMED (China) Limited ( HCM ) Q2 2023 Earnings Call Transcript Hutchmed starts registration phase for cancer trials after talks with Chinese regulator Hu...

HCM - HUTCHMED Announces that the Sovleplenib Phase III ESLIM-01 Study Met Its Primary Endpoint in Primary Immune Thrombocytopenia in China

— Randomized, double-blind, controlled trial met primary endpoint of durable response rate and all secondary endpoints — — Overall safety consistent with sovleplenib known profile — — Plans for regulatory submission underway in China,...
Previous 10 Next 10